United Therapeutics (UTHR) Projected to Post Quarterly Earnings on Wednesday

United Therapeutics (NASDAQ:UTHR) will likely be announcing its earnings results before the market opens on Wednesday, February 19th. Analysts expect United Therapeutics to post earnings of $6.54 per share and revenue of $734.74 million for the quarter.

United Therapeutics Trading Up 2.2 %

UTHR stock opened at $353.31 on Wednesday. The firm’s 50-day moving average is $362.06 and its two-hundred day moving average is $358.24. The company has a market capitalization of $15.78 billion, a price-to-earnings ratio of 15.52, a price-to-earnings-growth ratio of 0.92 and a beta of 0.57. United Therapeutics has a 52 week low of $210.64 and a 52 week high of $417.82.

Insiders Place Their Bets

In other United Therapeutics news, EVP Paul A. Mahon sold 7,700 shares of United Therapeutics stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $367.36, for a total value of $2,828,672.00. Following the transaction, the executive vice president now directly owns 36,710 shares of the company’s stock, valued at $13,485,785.60. The trade was a 17.34 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $348.06, for a total value of $3,480,600.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $896,950.62. This represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 121,864 shares of company stock valued at $44,516,965 over the last 90 days. 11.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages have issued reports on UTHR. HC Wainwright increased their price target on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. TD Cowen boosted their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Oppenheimer raised their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. The Goldman Sachs Group increased their price objective on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. Finally, StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $382.08.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.